149 related articles for article (PubMed ID: 11249591)
1. Effectiveness of fluoroquinolones against gram-positive bacteria.
Bush K; Goldschmidt R
Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of action and resistance of older and newer fluoroquinolones.
Hooper DC
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S24-8. PubMed ID: 10984324
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
4. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to fluoroquinolones.
Rattan A
Natl Med J India; 1999; 12(4):162-4. PubMed ID: 10573971
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
7. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
[TBL] [Abstract][Full Text] [Related]
8. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
9. 3-aminoquinazolinediones as a new class of antibacterial agents demonstrating excellent antibacterial activity against wild-type and multidrug resistant organisms.
Ellsworth EL; Tran TP; Showalter HD; Sanchez JP; Watson BM; Stier MA; Domagala JM; Gracheck SJ; Joannides ET; Shapiro MA; Dunham SA; Hanna DL; Huband MD; Gage JW; Bronstein JC; Liu JY; Nguyen DQ; Singh R
J Med Chem; 2006 Nov; 49(22):6435-8. PubMed ID: 17064062
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus.
Horii T; Suzuki Y; Takeshita A; Maekawa M
Chemotherapy; 2007; 53(2):104-9. PubMed ID: 17202817
[TBL] [Abstract][Full Text] [Related]
11. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
[TBL] [Abstract][Full Text] [Related]
12. Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid.
Johnson AP; Mushtaq S; Warner M; Livermore DM
Int J Antimicrob Agents; 2004 Oct; 24(4):315-9. PubMed ID: 15380254
[TBL] [Abstract][Full Text] [Related]
13. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
[TBL] [Abstract][Full Text] [Related]
14. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
Huang YT; Liao CH; Teng LJ; Hsueh PR
Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
[TBL] [Abstract][Full Text] [Related]
15. [Investigating the fluoroquinolone molecular resistant mechanism of Stenotrophomonas maltophilia].
Tao CM; Lü XJ; Li P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):266-9. PubMed ID: 16608091
[TBL] [Abstract][Full Text] [Related]
16. Quinolone antimicrobial agents: mechanism of action and resistance development.
Bryan LE; Bedard J; Wong S; Chamberland S
Clin Invest Med; 1989 Feb; 12(1):14-9. PubMed ID: 2537696
[TBL] [Abstract][Full Text] [Related]
17. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients.
Ashour HM; el-Sharif A
J Clin Oncol; 2007 Dec; 25(36):5763-9. PubMed ID: 18089873
[TBL] [Abstract][Full Text] [Related]
18. Fluoroquinolone antibacterials: SAR mechanism of action, resistance, and clinical aspects.
Gootz TD; Brighty KE
Med Res Rev; 1996 Sep; 16(5):433-86. PubMed ID: 8865150
[No Abstract] [Full Text] [Related]
19. Mechanisms of quinolone resistance.
Wiedemann B; Heisig P
Infection; 1994; 22 Suppl 2():S73-9. PubMed ID: 7927834
[TBL] [Abstract][Full Text] [Related]
20. Reversal of antibiotic resistance in Gram-positive bacteria by the antihistaminic azelastine.
El-Nakeeb MA; Abou-Shleib HM; Khalil AM; Omar HG; El-Halfawy OM
APMIS; 2012 Mar; 120(3):215-20. PubMed ID: 22339679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
